Peptide Ocular Drug Delivery: Eye Drops, Injections, and Implants for Peptide Eye Drugs

Eye diseases affect hundreds of millions of people worldwide. Many of the most serious conditions, including age-related macular degeneration and diabetic retinopathy, destroy vision and have limited treatments.

Peptide drugs offer new hope. But getting them into the right part of the eye is one of the hardest drug delivery challenges in medicine.

Why the Eye Is a Unique Delivery Challenge

The eye is designed to protect itself. Multiple barriers prevent most drugs from reaching the tissues inside the eye where they are needed.

The tear film washes the eye surface every few seconds. Eye drops placed on the eye are mostly drained away within 5 minutes. Only about 1-5% of an eye drop dose actually absorbs into the eye tissue.

The cornea is a dense, layered tissue. Its surface is water-loving (hydrophilic), its middle is fat-loving (lipophilic), and its inner layers are hydrophilic again. A drug must be both water-soluble and somewhat fat-soluble to pass through. Most peptides are too hydrophilic to penetrate the cornea efficiently.

The blood-retinal barrier is similar to the blood-brain barrier. It prevents drugs in the bloodstream from entering the sensitive retinal tissue at the back of the eye.

For diseases of the back of the eye (retina, choroid, vitreous), none of the surface barriers matter because eye drops cannot even reach there. Direct injection into the eye is usually required.

"The eye is almost too well protected. Every defense it has against infection and injury also works against therapeutic molecules. Peptide drug delivery in ophthalmology requires creative formulation strategies at every stage." - Dr. Uday Kompella, University of Colorado

Eye Anatomy: Why Location Matters So Much

The eye is divided into segments. Each segment needs a different delivery approach.

Eye Region	Location	Common Diseases	Best Delivery Route
Cornea	Front surface	Dry eye, infections, corneal wounds	Eye drops, corneal inserts
Conjunctiva	White of the eye	Dry eye, allergies, conjunctivitis	Eye drops
Anterior chamber	Behind the cornea	Glaucoma	Eye drops, intracameral injection
Vitreous	Gel filling the eye	Retinal diseases	Intravitreal injection
Retina	Back of the eye	AMD, diabetic retinopathy	Intravitreal injection, implant
Choroid	Layer behind retina	Choroidal neovascularization	Intravitreal or suprachoroidal

The human eye replaces its entire tear film every 2 to 5 minutes, which means a standard eye drop has only seconds of contact time before being washed away.

Eye Drops: Simple But Limited

Eye drops are the most convenient way to deliver drugs to the eye. Patients can self-administer them at home. But for peptide drugs, eye drops have serious limitations.

The main problems are:

• Rapid drainage: Tears drain the eye within minutes. Most of the drug is lost.
• Corneal barrier: The cornea blocks most peptides from entering the eye.
• Nasolacrimal drainage: Drained drug can enter the nose and be absorbed systemically, causing side effects.
• Low bioavailability: Typically less than 5% of the applied dose enters the ocular tissue.

Despite these limitations, eye drops are the preferred route for front-of-eye (anterior segment) diseases because they are non-invasive and patients accept them well.

Improving Eye Drop Formulations for Peptides

Formulators have developed several strategies to improve eye drop performance:

Mucoadhesive polymers: Hyaluronic acid, carbopol, and HPMC increase the viscosity of the drop. The thick solution does not drain as quickly. This extends drug contact time with the cornea.

Nanoparticle eye drops: Encapsulating the peptide in chitosan nanoparticles or lipid nanoparticles improves corneal penetration and reduces drainage. Nanoparticles can fuse with corneal cells and deliver the peptide inside.

Cyclodextrins: These ring-shaped sugar molecules form complexes with peptides and increase their solubility and corneal permeation.

Permeation enhancers: Low concentrations of surfactants, EDTA, or bile salts can temporarily loosen corneal cell junctions to improve peptide penetration. Safety and concentration limits are carefully studied.

Lacritin is a naturally occurring peptide in human tears that promotes tear secretion. It is being studied as an eye drop drug for dry eye disease, and is a good example of a peptide designed specifically for the ocular surface.

Intravitreal Injections: Direct Access to the Retina

For diseases of the back of the eye, the most effective delivery method is injecting the drug directly into the vitreous humor. This is called an intravitreal injection.

The vitreous is the clear gel that fills the inside of the eye. Drugs injected here can diffuse to the retina and other posterior structures. This bypasses all of the external eye barriers.

Intravitreal injection has become the standard of care for age-related macular degeneration. Anti-VEGF protein drugs (ranibizumab/Lucentis, aflibercept/Eylea, bevacizumab/Avastin) are given by intravitreal injection and have saved the vision of millions of patients.

These anti-VEGF drugs are peptides or proteins. Their success has made the ophthalmic field receptive to new peptide and protein drugs delivered the same way.

The Intravitreal Injection Procedure

The procedure takes only minutes but requires a skilled ophthalmologist:

1. The eye is numbed with anesthetic drops
2. The eye surface is cleaned with antiseptic
3. A very thin needle (typically 30-gauge) is inserted into the white of the eye at a specific angle
4. A small volume (usually 50-100 microliters) is injected into the vitreous
5. The needle is removed and the eye is checked for pressure

Patients receive these injections monthly or every 2-3 months for many retinal diseases. The burden of frequent injections has driven strong demand for longer-acting formulations that require fewer clinic visits.

When evaluating ocular peptide delivery platforms, prioritize candidates with mucoadhesive or nanoparticle formulations that extend corneal contact time, and recruit formulation scientists with direct experience in ocular pharmacokinetics to avoid costly late-stage reformulation.

Sustained-Release Ocular Implants: Fewer Injections

Sustained-release implants are placed inside the eye and release drug slowly over months or years. They reduce the injection burden dramatically.

Several implant technologies exist: For additional context, the NIH National Library of Medicine research database offers relevant guidance on this topic.

Implant Type	Material	Release Duration	Example
Biodegradable insert	PLGA	Months	Surodex (dexamethasone)
Non-biodegradable implant	Silicone/EVA	Years	Retisert (fluocinolone)
Injectable biodegradable implant	PLGA or hydrogel	Months	Ozurdex (dexamethasone rod)
Suprachoroidal sustained release	Biopolymer	4-6 months	In development
Port delivery system	Implanted reservoir	Refillable	Susvimo (ranibizumab)

Ozurdex is a biodegradable PLGA rod that is injected into the vitreous using a special applicator. It releases dexamethasone over 4-6 months and then dissolves. This design is directly applicable to peptide drugs.

Susvimo is a tiny refillable port implanted in the eye wall. The ophthalmologist refills it with drug every 6 months in the office, avoiding repeated intravitreal injections. This is specifically designed for chronic retinal diseases.

For peptide drugs, biodegradable PLGA-based implants are the most common development approach. PLGA's track record in other applications gives a clear regulatory pathway.

Challenges With Ocular Peptide Implants

Peptide stability: Peptides loaded into PLGA implants must survive months of slow degradation. PLGA creates an acidic microenvironment as it breaks down, which can damage sensitive peptides. Stabilizers and careful PLGA selection help.

Protein aggregation: In the vitreous, released peptide can aggregate at the injection site. This can trigger inflammation and reduce efficacy. Formulation scientists work to minimize aggregation in the release medium.

Sterilization: All ocular products must be sterile. Terminal sterilization (autoclaving) often damages peptides. Aseptic manufacturing or gamma irradiation are alternatives, each with their own challenges.

Topical Ophthalmic Peptide Formulation Requirements

For eye drop formulations, several quality standards must be met:

• Sterility: All products must pass sterility tests
• Isotonicity: Near-isotonic solutions are better tolerated (280-300 mOsm)
• pH: Range of 6.8-7.8 to avoid irritation
• Viscosity: Too thin drains fast; too thick is uncomfortable
• Preservatives: Benzalkonium chloride is common but toxic to corneal cells over time; preservative-free options are preferred for frequent dosing
• Particle size: Suspensions must be sterile with controlled particle size

Peptides in Clinical Development for Ocular Diseases

Several peptides are in active clinical trials for eye diseases:

• Anti-VEGF peptides: Smaller alternatives to full antibodies for macular degeneration
• Integrin-binding peptides (RGD-based): For choroidal neovascularization
• Compstatin analogs: Complement inhibitors for dry AMD and geographic atrophy
• Angiopoietin peptide analogs: For diabetic retinopathy
• Peptide nerve growth factor (NGF) mimetics: For corneal nerve regeneration in dry eye and neurotrophic keratitis

"Peptide drugs are an ideal fit for ophthalmology. Their smaller size compared to full antibodies means better tissue penetration and potentially longer duration in the vitreous. The field is very active." - Dr. Michael Goldberg, Chief Medical Officer, Ophthotech

---

FAQs About Peptide Ocular Drug Delivery

Why can't I just take a pill for eye diseases like macular degeneration?

Oral drugs taken systemically do not reach the retina in effective concentrations because of the blood-retinal barrier. You would need very high oral doses to get even small amounts into the retina, which would cause systemic side effects. Direct ocular delivery avoids this by putting the drug exactly where it is needed.

Are intravitreal injections painful?

Most patients report minimal pain during intravitreal injections when proper anesthesia is used. The pressure sensation during injection is often more noticeable than pain. The fear of the procedure is usually worse than the procedure itself. Patients who receive many injections typically say they tolerate them well over time.

How often do patients need intravitreal injections for retinal diseases?

For conditions like wet AMD, monthly injections are sometimes needed initially. Many patients transition to every 2-3 months. This injection burden is why sustained-release formulations that last 4-12 months are such a high priority in ophthalmic drug development.

What is the difference between biodegradable and non-biodegradable ocular implants?

Biodegradable implants (like PLGA rods) release drug as the polymer breaks down, then disappear completely. Non-biodegradable implants (like silicone rings) release drug continuously and remain in the eye indefinitely. Non-biodegradable implants can theoretically be refilled or removed but require a second procedure. Biodegradable implants are simpler but have a limited duration.

Can nanoparticles be used in eye drops to improve peptide delivery?

Yes. Nanoparticles made from chitosan, PLGA, or lipids have shown improved corneal penetration and longer retention in the eye compared to peptide solutions in research studies. Several companies are developing nanoparticle-based eye drops. None are yet approved for peptides, but this is an active area of commercialization.

---

Recruit Ocular Peptide Drug Delivery Experts With PeptideStaff

Ophthalmic peptide drug development needs scientists who understand both the unique challenges of the eye and the complexities of peptide formulation. This is a rare skill set.

PeptideStaff helps biotech and pharmaceutical companies find experienced ocular drug delivery scientists, formulation chemists, and regulatory specialists for peptide eye drug programs. We match you with professionals who have delivered results in this field before.

Contact PeptideStaff to find ocular peptide delivery experts for your program.